Raw Degarelix powder, also known as Raw Degarelix powder acetate and FE-200486, a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone. Raw Degarelix powder is specifically indicated for the treatment of advanced prostate cancer.
Raw Degarelix powder is supplied as a powder to be reconstituted with sterile water for subcutaneous administration in the abdomen. The recommended initial dose of the drug is 240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL. The recommended maintenance dose of Raw Degarelix powder is 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL, every 28 days. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. Product Name Raw Degarelix powder Chemical Name Raw Degarelix powder acetate; FE-200486; UNII-SX0XJI3A11; SX0XJI3A11; CS-5350; Z-3147; CHEMBL415606; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2; Sequence Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(L-Hor)-D4Aph(Cbm)-Leu-Lys(Ipr)-Pro-DAla-NH2 Drug Class Antineoplastic Agents CAS Number 214766-78-6 InChIKey MEUCPCLKGZSHTA-XYAYPHGZSA-N Molecular Formula C82H103ClN18O16 Molecular Weight 1632.28 Monoisotopic Mass 1630.75 g/mol g·mol−1 Melting Point N/A Freezing Point N/A Biological Half-Life 23~61 days Color White to off-white solid powder Solubility H2O: ≥ 500 mg/mL Storage Temperature -20°C Application Used to treat patients with advanced prostate cancer
|